Three direct trials have preliminary sponsor results. REDEFINE 4 in obesity failed to establish CagriSema noninferiority to tirzepatide for weight loss. In type 2 diabetes, higher-dose REIMAGINE 4 met weight noninferiority but failed the glucose criterion; lower-dose REIMAGINE 5 reported greater weight loss with CagriSema and met glucose noninferiority. Exact doses, populations and analysis assumptions determine what each result means.
Research reviewed October 15, 2026. Educational information only.
A dual agonist and a two-peptide combination
Tirzepatide is one peptide that activates receptors for GIP and GLP-1, two hormones involved in glucose regulation. CagriSema combines two different peptides: semaglutide, which activates GLP-1 receptors, and cagrilintide, a long-acting analogue of the hormone amylin. Amylin-related signalling helps regulate fullness and food intake. The two approaches therefore share GLP-1 activity while adding different biology.
The current Zepbound label describes an approved tirzepatide product. Novo Nordisk’s September 2026 announcement describes CagriSema as investigational. A particular manufactured combination and trial dose require their own evidence; the individual semaglutide label cannot serve as approval for CagriSema.
The main differences
What did the higher-dose obesity comparison show?
REDEFINE 4 was an open-label 84-week trial in 809 adults with obesity and at least one other condition. The following are preliminary sponsor results for CagriSema 2.4 mg/2.4 mg versus tirzepatide 15 mg. The main comparison failed to establish CagriSema noninferiority; the announcement did not provide its full confidence interval or noninferiority margin.
Tirzepatide
Average weight loss was 23.6% when treatment stopping was included, and 25.5% in the separate analysis assuming adherence. Both were numerically greater than the corresponding CagriSema estimates; the failed noninferiority test alone is not a demonstrated prespecified superiority result.
CagriSema
Average weight loss was 20.2% when treatment stopping was included, and 23.0% assuming adherence. CagriSema did not meet the trial’s criterion for being no worse than tirzepatide by the allowed margin. These preliminary findings apply to the 2.4 mg/2.4 mg trial combination.
What did the two direct diabetes comparisons show?
Both trials enrolled adults with type 2 diabetes. REIMAGINE 4 required inadequate control on metformin with or without an SGLT2 inhibitor and tested CagriSema 2.4 mg/2.4 mg versus tirzepatide 15 mg for 68 weeks. REIMAGINE 5 allowed metformin, an SGLT2 inhibitor or both and tested 1.0 mg/1.0 mg versus 5 mg for 60 weeks. These preliminary sponsor estimates assume adherence. HbA1c reflects average glucose exposure over preceding weeks and months; full confidence intervals were not supplied.
Tirzepatide
In REIMAGINE 4, tirzepatide 15 mg produced 15.8% average weight loss and a 2.2-percentage-point HbA1c reduction. In the separate REIMAGINE 5 trial, tirzepatide 5 mg produced 9.1% weight loss and a 1.67-point HbA1c reduction. The trials cannot isolate a causal effect of changing dose.
CagriSema
In REIMAGINE 4, CagriSema 2.4 mg/2.4 mg produced 15.2% weight loss and a 1.9-point HbA1c reduction: weight noninferiority was met, glucose noninferiority failed. In REIMAGINE 5, 1.0 mg/1.0 mg produced 12.4% weight loss and a 1.71-point HbA1c reduction; the sponsor reported superior weight loss and noninferior glucose lowering versus tirzepatide 5 mg.
What differs in the molecules and current product status?
Both approaches include GLP-1 receptor activation, which contributes to appetite and glucose regulation. Tirzepatide adds GIP receptor activity in one peptide; CagriSema adds a separate amylin analogue to semaglutide. Product status below follows the official label and dated sponsor report.
Tirzepatide
Tirzepatide is one peptide acting at GIP and GLP-1 receptors. Zepbound is an FDA-approved tirzepatide product with defined weight-management and obstructive-sleep-apnea indications and its own warnings.
CagriSema
CagriSema combines semaglutide with cagrilintide, a long-acting amylin analogue. The September 2026 sponsor report describes it as investigational. Its 1.0 mg/1.0 mg and 2.4 mg/2.4 mg trial combinations cannot be treated as one interchangeable dose.
Sources
- Novo Nordisk (23 February 2026). CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved. Company announcement.
- Novo Nordisk (21 September 2026). Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. Company announcement.
What do pharmacokinetic studies show about time in blood?
An elimination half-life describes the time blood concentration takes to fall by half. The values below come from different human pharmacokinetic sources and do not establish comparative weight loss. The CagriSema ingredients were measured separately.
Tirzepatide
The current Zepbound label reports an elimination half-life of approximately five to six days in people with overweight or obesity, including those with obesity and obstructive sleep apnea. This approximate range is not a statistical confidence interval.
CagriSema
In Enebo and colleagues’ phase 1b coadministration study, 95 participants received treatment: cagrilintide half-life was 159–195 hours and semaglutide half-life 145–165 hours across studied groups. These are group-estimate ranges, not confidence intervals or one shared combination half-life.
Do the direct reports establish which is easier to tolerate?
All three direct comparisons use preliminary sponsor summaries in this review. Missing complete event denominators, serious-event tables and treatment-stopping counts limit a tolerability ranking.
Tirzepatide
The approved label describes digestive reactions and important pancreatic, gallbladder, kidney and thyroid-related warnings. The preliminary direct-trial reports do not provide enough comparative safety data to establish an advantage over CagriSema.
Sources
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: U.S. prescribing information. Revised August 2026. DailyMed.
- Novo Nordisk (23 February 2026). CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved. Company announcement.
- Novo Nordisk (21 September 2026). Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. Company announcement.
- Novo Nordisk. Financial report for the period 1 January 2026 to 30 June 2026. Company announcement No 48/2026. August 4, 2026.
CagriSema
The sponsor describes mostly mild or moderate digestive events in REDEFINE 4 and tolerability consistent with prior studies in the two diabetes trials. Without full event and treatment-stopping counts, these descriptions cannot establish lower risk than tirzepatide.
Sources
- Novo Nordisk (23 February 2026). CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved. Company announcement.
- Novo Nordisk (21 September 2026). Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. Company announcement.
- Novo Nordisk. Financial report for the period 1 January 2026 to 30 June 2026. Company announcement No 48/2026. August 4, 2026.
The higher-dose obesity trial did not meet its planned comparison
Novo Nordisk’s February 23, 2026 preliminary report describes REDEFINE 4, an 84-week trial in 809 adults with obesity and at least one other condition. Participants and investigators knew which treatment was given. Weekly injections compared CagriSema 2.4 mg cagrilintide plus 2.4 mg semaglutide with tirzepatide 15 mg. The report does not provide arm-specific participant counts or complete confidence intervals.
When estimating weight change regardless of whether participants stayed on treatment, average loss was 20.2% with CagriSema and 23.6% with tirzepatide. Under the separate analysis assuming treatment adherence, the estimates were 23.0% and 25.5%. These analyses answer different questions and should be compared within the same row.
The trial’s primary aim was to show that CagriSema was not unacceptably worse than tirzepatide by a prespecified margin, a test called noninferiority. That criterion was not met. CagriSema’s numerical weight loss was lower, but a failed noninferiority test alone does not establish that a prespecified superiority test proved tirzepatide better. The preliminary announcement does not give the margin or full confidence interval needed to inspect that test in detail.
The higher-dose diabetes trial met one criterion and missed another
Novo Nordisk’s August 4, 2026 quarterly report describes another direct comparison, REIMAGINE 4. This open-label, 68-week trial tested CagriSema 2.4 mg/2.4 mg against tirzepatide 15 mg in adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor.
In the analysis assuming treatment adherence, average weight loss was 15.2% with CagriSema and 15.8% with tirzepatide. HbA1c fell 1.9 and 2.2 percentage points, respectively. CagriSema met the trial’s noninferiority criterion for weight reduction but failed to meet it for HbA1c reduction. Thus the trial did not establish that its glucose lowering was within the allowed margin of tirzepatide. This preliminary sponsor summary did not give participant counts, complete confidence intervals or the margins needed to inspect the comparisons fully.
The lower-dose diabetes trial asked a different question
The September 21, 2026 sponsor announcement reports REIMAGINE 5 in adults with type 2 diabetes inadequately controlled with metformin, an SGLT2 inhibitor or both. It compared CagriSema 1.0 mg/1.0 mg with tirzepatide 5 mg over 60 weeks. These doses differ from REDEFINE 4, as do the population and follow-up. The report labels the quoted results as an efficacy analysis, estimating outcomes with continued treatment.
Average weight loss was 12.4% with CagriSema and 9.1% with tirzepatide; the sponsor reported superiority for weight. HbA1c, which reflects average glucose exposure over preceding weeks and months, fell 1.71 percentage points with CagriSema and 1.67 points with tirzepatide, meeting the reported noninferiority criterion. That glucose result does not establish greater glucose lowering with CagriSema. Full confidence intervals and complete safety tables were not supplied in the announcement.
The apparent change in which group lost more weight is therefore understandable without treating either report as a contradiction. Different dose pairs were studied in different populations. Neither result can be extended to every dose, to an individual’s response or to untested mixtures of the ingredients.
Pharmacokinetics: two measured peptide profiles
The current Zepbound label reports a tirzepatide elimination half-life of approximately five to six days in people with overweight or obesity. This describes the time blood concentration takes to fall by half during elimination. It does not specify how much weight someone will lose.
Enebo and colleagues’ 2021 phase 1b study measured cagrilintide and semaglutide separately after coadministration in adults with overweight or obesity. Of 96 randomized participants, 95 received study treatment. Across the tested cagrilintide groups, cagrilintide half-life was 159–195 hours and semaglutide half-life was 145–165 hours. The reported ranges describe study-group estimates, not confidence intervals. Cagrilintide did not materially change semaglutide exposure or elimination in this study.
Those measurements explain why giving two peptides together does not produce one scientifically meaningful “CagriSema half-life.” They also come from an early coadministration study, rather than a direct pharmacokinetic comparison with tirzepatide in REDEFINE 4 or REIMAGINE 5.
What is known about side effects?
The REDEFINE 4 preliminary report describes mostly mild or moderate digestive adverse events with CagriSema, diminishing over time. The REIMAGINE 5 announcement describes its safety profile as consistent with earlier studies. The REIMAGINE 4 quarterly summary likewise describes tolerability without detailed comparative counts. None of these reports supplies a full set of arm-specific event counts, serious-event tables and treatment-stopping rates. They cannot establish that CagriSema is easier to tolerate than tirzepatide across the compared settings.
Tirzepatide’s approved label includes digestive adverse reactions and warnings concerning severe stomach or intestinal reactions, pancreatic inflammation, gallbladder disease, kidney injury associated with fluid loss and other risks. It carries a boxed thyroid C-cell tumor warning based on animal findings, with uncertain human relevance. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are contraindications. A label for an approved ingredient provides useful context, while the full combination still requires its own benefit-risk assessment.
Read the dose, population and analysis together
The most useful comparison begins with the actual trial question. In REDEFINE 4’s obesity population, weight loss was numerically greater with tirzepatide and the CagriSema noninferiority criterion failed. In the higher-dose REIMAGINE 4 diabetes comparison, weight noninferiority was met but glucose noninferiority failed. In the lower-dose REIMAGINE 5 diabetes comparison, the sponsor reports greater weight loss with CagriSema and glucose lowering that met noninferiority.
These results support specific statements about each trial while leaving a broad treatment ranking unresolved. The trials do not establish that the dose difference caused the different findings. Complete reports would help assess uncertainty, treatment stopping, achieved doses and adverse events alongside the averages.
Frequently asked questions
Why do the three direct reports give different results?
The trials tested different populations, dose pairs and durations: REDEFINE 4 in obesity, higher-dose REIMAGINE 4 in diabetes, and lower-dose REIMAGINE 5 in diabetes. Each comparison answers its own question; the different findings cannot be attributed solely to dose or collapsed into one ranking.
Does failed noninferiority prove tirzepatide was superior?
The trial failed to establish that CagriSema was within the allowed loss-of-effect margin. Its weight loss was also numerically lower. A separate prespecified superiority test would be needed to claim demonstrated superiority; the preliminary announcement does not provide that result or a full confidence interval.
Does REIMAGINE 5 show greater glucose lowering with CagriSema?
The sponsor reported HbA1c reductions of 1.71 and 1.67 percentage points for CagriSema and tirzepatide and described the result as noninferior. That meets a criterion for being no worse by the allowed margin, rather than establishing greater glucose lowering. Weight loss was reported as superior in that particular comparison.
Why are two percentages quoted for each REDEFINE 4 group?
The treatment-regimen analysis estimates effects regardless of treatment adherence and gives 20.2% for CagriSema and 23.6% for tirzepatide. The efficacy analysis assumes adherence and gives 23.0% and 25.5%. The percentages should be compared within the same analysis.
Does CagriSema have one half-life?
Its two ingredients have separate measured concentration profiles. The early coadministration study reported different half-life ranges for cagrilintide and semaglutide; neither can be presented as one measured half-life for the combination.
Are these direct results full journal publications?
This article uses dated preliminary sponsor reports for the three direct comparisons. The early coadministration pharmacokinetic study is a journal publication. Full direct-trial reports would be needed to inspect confidence intervals, detailed safety and treatment stopping beyond the summaries.
What did the higher-dose diabetes trial add?
REIMAGINE 4 reported 15.2% weight loss and a 1.9-point HbA1c fall with CagriSema 2.4 mg/2.4 mg, versus 15.8% and 2.2 points with tirzepatide 15 mg at 68 weeks, assuming adherence. Weight met noninferiority, but glucose lowering did not. The full uncertainty and prespecified margins were absent from this preliminary summary.
Profiles and related reading
References
- Novo Nordisk (23 February 2026). CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved. Company announcement.
Complete original sponsor announcement freshly read October15,2026. No full peer-reviewed comparison report acquired; full uncertainty and comparative safety tables absent from announcement. Complete February 23,2026report:809randomized,84weeks; weight23.0/25.5%assuming adherence,20.2/23.6%regardless adherence; endnotes1–2.
- Novo Nordisk (21 September 2026). Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. Company announcement.
Complete original September21,2026sponsor announcement freshly read October15,2026. It also reports REDEFINE9; the article does not pool those trials. Full journal report not acquired. REIMAGINE5row:1.0/1.0mgversus5mgtirzepatide,60weeks,weight12.4/9.1%,HbA1c1.71/1.67points; efficacy-estimand footnote.
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: U.S. prescribing information. Revised August 2026. DailyMed.
Complete original official source freshly read October 15, 2026. Sections1,4–5,11–12.3; August2026revision.
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets: U.S. prescribing information. Revised June 2026. DailyMed.
Complete original official source freshly read October 15, 2026. Sections4–5and12.1–12.3.
- Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736–1748. doi:10.1016/S0140-6736(21)00845-X.
Original PubMed abstract and original indexed ScienceDirect abstract freshly read October15,2026; complete paper not acquired. PubMed linked comment is commentary, not a correction or retraction. Abstract Methods/Findings:96randomized/95exposed,20weeks plus5weeks follow-up; cagrilintide159–195h,semaglutide145–165h; exposure/elimination interaction.
- Novo Nordisk. Financial report for the period 1 January 2026 to 30 June 2026. Company announcement No 48/2026. August 4, 2026.
Original SEC-hosted full company filing and37-pageoriginal company PDF freshly read October15,2026; preliminary sponsor summary, not a full clinical journal report. No armcounts, confidenceintervals or noninferioritymargin provided. Printed page20: CagriSema, Completion of the open-label head-to-head REIMAGINE4trial; dual primary outcomes and adherence-assuming estimates.